These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2963347)

  • 21. Pharmacological modification of lipoprotein metabolism.
    Shepherd J; Packard CJ
    Biochem Soc Trans; 1987 Apr; 15(2):199-201. PubMed ID: 3556260
    [No Abstract]   [Full Text] [Related]  

  • 22. Lipid lowering agents.
    Br Med J; 1972 Jun; 2(5814):642-3. PubMed ID: 5031693
    [No Abstract]   [Full Text] [Related]  

  • 23. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drugs in hyperlipidemia].
    Stuyt PM
    Ned Tijdschr Geneeskd; 1987 Sep; 131(36):1554-8. PubMed ID: 3670435
    [No Abstract]   [Full Text] [Related]  

  • 25. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.
    Carlson LA
    J Intern Med; 2005 Aug; 258(2):94-114. PubMed ID: 16018787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A; Rovellini A; Fiorenza AM; Sommariva D
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
    Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F;
    Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New perspectives on the use of niacin in the treatment of lipid disorders.
    McKenney J
    Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lowering of serum lipid concentrations: mechanisms used by unsaturated fats, nicotinic acid, and neomycin: excretion of sterols and bile acids.
    GOLDSMITH GA; HAMILTON JG; MILLER ON
    Arch Intern Med; 1960; 105():512-7. PubMed ID: 13848368
    [No Abstract]   [Full Text] [Related]  

  • 30. [The pharmacological effects of certain compounds on lipoprotein(a)].
    Monte G; Mezdour H
    Recenti Prog Med; 1993 Dec; 84(12):855-63. PubMed ID: 8108601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Indications for surgical treatment and medical treatment of atherosclerosis].
    Paredero Del Bosque Martin V
    Minerva Med; 1980 Oct; 71(40):2963-7. PubMed ID: 7454082
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effect of sorbinicate on blood proteins and platelet aggregation in patients with coronary disease].
    Bonfiglioli D; Sommariva D; Rovelli L; Panigo F; Gatti P; Cialfi A; Grimoldi M; Cabrini E; Fasoli A
    Clin Ter; 1984 Jul; 110(2):111-8. PubMed ID: 6237851
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice.
    Kawamura I; Yamamoto N; Sakai F; Yamazaki H; Goto T
    Anticancer Res; 1999; 19(5B):4099-103. PubMed ID: 10628360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The significance of lipoprotein(a) in assessment of risk for atherosclerosis].
    Kullich W; Machreich K
    Wien Med Wochenschr; 1994; 144(17):407-11. PubMed ID: 7839688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of bezafibrate on HDL with APO A-I and APO A-II and on HDL with APO A-I without APO A-II in hyperlipidaemic patients.
    Branchi A; Rovellini A; Sommariva D
    Int J Clin Pharmacol Res; 1995; 15(4):153-8. PubMed ID: 8871265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [When should an association of lipid-lowering drugs be proposed in a patient failing to reach therapeutic targets under monotherapy? Guidelines of the New French Society of Atherosclerosis].
    Farnier M; Bonnet F; Bruckert E; Ferrières J; Paillard F;
    Arch Mal Coeur Vaiss; 2007; 100(6-7):569-81. PubMed ID: 17893640
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug interactions and side effects of hypolipidemic drugs.
    Schwandt P
    Int J Clin Pharmacol Biopharm; 1979 Aug; 17(8):351-6. PubMed ID: 489202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [DRUGS AGAINST HYPERCHOLESTEROLEMIA].
    MENESESHOYOS J
    Medicina (Mex); 1964 Jul; 44():353-9. PubMed ID: 14183514
    [No Abstract]   [Full Text] [Related]  

  • 39. Mechanisms by which certain pharmacologic agents lower serum cholesterol.
    GOLDSMITH GA
    Fed Proc; 1962; 21(4)Pt 2():81-5. PubMed ID: 13899859
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of nicotinic acid on serum-lipids in normal and atherosclerotic subjects.
    GALBRAITH PA; PERRY WF; BEAMISH RE
    Lancet; 1959 Jan; 1(7066):222-3. PubMed ID: 13631973
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.